Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. Thibaudin M, et al. Among authors: borg c. Nat Med. 2023 Aug;29(8):2087-2098. doi: 10.1038/s41591-023-02497-z. Epub 2023 Aug 10. Nat Med. 2023. PMID: 37563240 Free PMC article. Clinical Trial.
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L. Ménard C, et al. Among authors: borg c. Cancer Res. 2009 Apr 15;69(8):3563-9. doi: 10.1158/0008-5472.CAN-08-3807. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351841 Clinical Trial.
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY. Bennouna J, et al. Among authors: borg c. Clin Colorectal Cancer. 2012 Mar;11(1):38-44. doi: 10.1016/j.clcc.2011.05.002. Epub 2011 Jul 29. Clin Colorectal Cancer. 2012. PMID: 21803002 Clinical Trial.
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.
Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rébé C, Ghiringhelli F. Chalmin F, et al. Among authors: borg c. Immunity. 2012 Mar 23;36(3):362-73. doi: 10.1016/j.immuni.2011.12.019. Epub 2012 Mar 8. Immunity. 2012. PMID: 22406269 Free article.
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillère B, Tartour E, Borg C, Adotévi O. Godet Y, et al. Among authors: borg c. Clin Cancer Res. 2012 May 15;18(10):2943-53. doi: 10.1158/1078-0432.CCR-11-3185. Epub 2012 Mar 8. Clin Cancer Res. 2012. PMID: 22407833 Free article.
Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C. Dobi E, et al. Among authors: borg c. Clin Colorectal Cancer. 2013 Mar;12(1):28-36. doi: 10.1016/j.clcc.2012.09.002. Epub 2012 Oct 17. Clin Colorectal Cancer. 2013. PMID: 23083634
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Among authors: borg c. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
451 results